Cohance Lifescience
Cohance Lifesciences is a global, innovation-led CDMO specializing in ADC payloads, linker-payloads, HPAPIs, APIs, and advanced therapeutics. Through its partnership with NJ Bio, Cohance offers an integrated ADC platform spanning payload-linker design, bioconjugation, in vivo testing, GMP manufacturing, and commercial supply. Its portfolio includes key ADC payloads such as SN-38, Exatecan, MMAE, and (S)-Trione, supported by scalable manufacturing, regulatory expertise, and USFDA-approved facilities, enabling seamless advancement from discovery to commercialization.
